再鼎内部管线出现转折点,应该被世界看见。再鼎医药发起一场世界级的闪电战,在SCLC(小细胞肺癌)治疗变革的窗口期,其核心管线zocilurtatug pelitecan(简称Zoci,前称ZL-1310)从I期研究推进至全球注册性研究用时不到2年,全球开发速度领先同类药物1.5年以上,从而有望跻身SCLC新型标准治疗之列。Zoci最新I期临床数据入选AACR-NCI-EORTC口头报告,1.6mg...
Source Link再鼎内部管线出现转折点,应该被世界看见。再鼎医药发起一场世界级的闪电战,在SCLC(小细胞肺癌)治疗变革的窗口期,其核心管线zocilurtatug pelitecan(简称Zoci,前称ZL-1310)从I期研究推进至全球注册性研究用时不到2年,全球开发速度领先同类药物1.5年以上,从而有望跻身SCLC新型标准治疗之列。Zoci最新I期临床数据入选AACR-NCI-EORTC口头报告,1.6mg...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.